




Svar Life Sciences Elisa Assays

Offering Elisa Assays to measure the functionality of the Human Complement System.

A valuable diagnostic tool in a number of clinical situations.

Saving time and effort in securing an accurate result for an informed diagnosis.

- · One test, three pathways
- · A unique diagnostic solution
- Proven correlation with haemolytic assays (CH50, APH50)
- *Special trial pricing available on request, contact Bio-Strategy today!





Contact us for more information and to place your orders

Bio-Strategy Pty Ltd.

T: 1800 008 453 E: sales.au@bio-strategy.com www.bio-strategy.com shop.bio-strategy.com



<u>linkedin.com/company/bio-strategy</u>

VALID UNTIL: 30 September 2021


Ref. Code: EURO-PRICE



ONE TEST - THREE PATHWAYS

A UNIQUE DIAGNOSTIC SOLUTION

Proven correlation with haemolytic assays (CH50, APH50)



The Svar Life Science Complement assay allows you to characterize the function of the three individual pathways of the complement system in a simple, objective ELISA format, saving time and effort in securing an accurate result for an informed diagnosis.

The Svar Life Science complement ELISA was developed in close collaboration with key opinion leaders and the design of the assay system allows for specific analysis of a chosen pathway without interference from another pathway.

The properties of the solution make it well-suited as an analytical tool for a range of disorders related to complement deficiency or dysfunction.

A VALUABLE DIAGNOSTIC TOOL IN A NUMBER OF CLINICAL SITUATIONS

The increased awareness and interest in the complement system has augmented the need for a simple and objective method to assess the function of complement activation.

Deficiencies of complement components are generally associated with an increased susceptibility to a wide range of infections. Beside deficiency of complement proteins, dysregulation of complement activity has been suspected to be involved in the development and progression of a number of diseases. In recent years, several disorders and clinical situations including therapy have been proven to be related to dysfunctional complement activity.

Simple to use and easy to interpret

The Svar Life Science complement ELISA is purposely designed to detect complement deficiencies with high accuracy. It is easy to use, results are intuitive to interpret (Table), and being in an ELISA format the assay can be used with a wide variety of open systems.

Classical Pathway	Lectin (MBL) Pathway	Alternative Pathway	Possible deficiency
Normal	Normal	Normal	NONE
Reduced ↓	Normal	Normal	C1q, C1r, Cls
Normal	Normal	Reduced ↓	Properdin, Factor B, Factor D
Normal	Reduced ↓	Normal	MBL, MASP2
Reduced ↓	Reduced ↓	Reduced ↓	C3, C5, C6, C7, C8, C9, Factor H*, Factor I*
Reduced ↓	Reduced ↓	Normal	C4, C2

^{*}Deficiency of Factor H and/or Factor I cause consumption of C3, i.e. secondary C3-deficiency and thereby reduced pathway activity.

The complement system is composed of at least 50 soluble and cell-bound proteins. Complement activation occurs as a cascade of proteolytic reactions through three separate pathways, each triggered by different molecules.

Methodology

The Svar Life Science complement ELISA combines principles of the functional hemolytic assay for complement activation with ease of use and objective ELISA format employing antibodies specific for a neoepitope exposed by the formation of the Terminal Complement Complex (TCC, C5b-9) as a result of complement activation.

The wells of the microtiter strips are coated with specific activators of the classical, or the lectin (MBL), or the alternative pathway. Patient serum is diluted in pathway specific diluent, designed to ensure that only the respective pathway is activated. During the incubation of the patient serum, complement is activated through each pathway by the specific coating. Finally, C5b-9 is detected, and the amount of C5b-9 generated is proportional to the functional activation of the particular complement pathway.

References

- Seelen MA, Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005 Jan;296(1-2):187-98
- Bjerre A, Mollnes TE et al. Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. Case Rep Nephrol. 2018 Dec 18;2018:3810249
- Ekdahl KN, Nilsson B et al. Interpretation of Serological Complement Biomarkers in Disease. Front Immunol. 2018 Oct 24:9:2237
- Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016 Jul;12(7):383-401
- Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol. 2019 Oct;114:299-311
- 6. Skattum L. Clinical Complement Analysis-An Overview. *Transfus Med Rev. 2019 Oct;33*(4):207-216
- Volokhina EB, Mollnes TE et al. Sensitive, reliable and easyperformed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol. 2015 Oct;160(2):237-43. 2013 Sep;84(3):441-50

SPECIFIC COATING Classical Pathway Lectin/MBL Pathway Alternative Pathway SPECIFIC BLOCKING **UNIVERSAL DETECTION** Classical Pathway Lectin/MBL Pathway Alternative Pathway

Product information

IVD	RUO				
COMPL 300 ¹	COMPL 300 RUO ²	ELISA kit for total functional assessment of total Complement System	3 x 32 wells break-apart		
COMPL CP310 ¹	COMPL CP310 RUO ²	ELISA kit for functional assessment of the Classical Pathway	96 wells break-apart		
COMPL MP3201	COMPL MP320 RUO ²	ELISA kit for functional assessment of the Lectin Pathway (MBL)	96 wells break-apart		
COMPL AP3301	COMPL AP330 RUO ²	ELISA kit for functional assessm ent of the Alternative Pathway	96 wells break-apart		

All devices are CE-marked for IVD use unless otherwise noted.

- ¹ Please contact your local representative for availability in your country, not available in US.
- ² For research use only, contact your local representative for research use availability in your country.

